The short answer
Mochi Health is our top pick for cash-pay compounded. Score 7.6 of 10. Flat $178 per month at every dose, the most transparent sourcing disclosure in the category, and a publicly stated continuity plan if a pharmacy partner is disrupted. The cleanest cash-pay compounded path we score.
The short version
Cash-pay compounded is a narrower category in 2026 than it was in 2023. The FDA declared the semaglutide shortage resolved in October 2024, and Eli Lilly's coordinated lawsuits against compounded tirzepatide pharmacies through 2024 to 2025 have closed several large 503A operators. The programs that still actively prescribe compounded are operating under clear regulatory exposure. The right pick balances price (the entire point of cash-pay compounded), pharmacy partner stability and an honest disclosure of what happens to your supply if the program's compounding pharmacy gets shut down.
What we considered
- All-in cash-pay monthly cost at maintenance dose (no surprise repricing at higher doses)
- 503A pharmacy partner stability and public disclosure
- Continuity plan if pharmacy partner is disrupted
- Clinical screening depth (not rubber-stamp async review)
- Cancellation flexibility (no annual lock-in on a regulatorily fluid category)
Top pick: Mochi Health
Mochi's flat $178 per month, transparent pharmacy partner disclosure and clinical screening that catches contraindications make it the cleanest cash-pay compounded path in the chart. The regulatory exposure is category-wide; Mochi handles it more honestly than competitors.
Read the full Mochi Health review →
Why Mochi Health won this category
Mochi's flat $178 monthly is the cheapest predictable cash-pay path in our chart that doesn't depend on insurance. The price holds across the entire titration ladder: same $178 at 0.25 mg as at 2.4 mg semaglutide. This matters because most compounded programs raise prices as you titrate up, so the headline starter price they sold you on bears no resemblance to month 4's bill.
The sourcing transparency is the editorial differentiator. Mochi publicly discloses their 503A pharmacy partners (or at least the regulatory status of each), publishes their continuity plan if a partner is shut down and has historically communicated proactively with patients during prior pharmacy disruptions. Most cash-pay compounded programs treat their pharmacy network as a trade secret, which leaves you exposed when enforcement lands. Mochi is the exception.
The clinical screening is real. Mochi's intake includes contraindication screening (medullary thyroid history, MEN-2, pancreatitis history) and a clinician sign-off before the script ships. Several of the cheapest cash-pay compounded programs use a rubber-stamp async review where the clinical depth is roughly nominal; Mochi's review is closer to what you'd get at a brand-prescribing telehealth program, which earns clinical-depth points in our scoring framework.
The trade-off is the regulatory exposure inherent to all compounded GLP-1 in 2026. The FDA's October 2024 shortage resolution narrows the operating window for 503A compounded semaglutide. Eli Lilly's lawsuits against compounded tirzepatide operators have closed several pharmacies. None of this is Mochi-specific, it's category-wide. Mochi handles it better than the alternatives, but the underlying regulatory exposure is real and the entire category could narrow further in 2026 to 2027.
Who this pick isn't for
Mochi is not the right pick if you have insurance that covers brand Wegovy or Zepbound. Cash-pay compounded at $178 monthly is great if your insurance won't cover GLP-1 weight loss, but a $25 to $50 monthly copay on brand Wegovy through PlushCare or Form Health is cheaper and lower regulatory exposure. Run your formulary check before signing up for any cash-pay compounded program.
Mochi is also not the right pick if you specifically want branded medication for regulatory clarity. Some patients have decided the compounded regulatory exposure isn't worth the cash-pay savings and prefer FDA-approved manufactured product. For brand-only cash-pay patients, Ro Body's $299 LillyDirect Zepbound or NovoCare's $199 to $499 Wegovy are the relevant alternatives.
And Mochi doesn't fit if you need stacked clinical care for comorbidities beyond obesity (T2D, MASH, PCOS, CV disease) that requires coordinated workup. Mochi's clinical depth is solid for the cash-pay compounded category but doesn't match a full primary-care model. Knownwell or Form Health are the right picks if your medical complexity exceeds what a single-condition telehealth program can manage.
Runner-up: Henry Meds
Henry Meds at flat $179 monthly is roughly tied on price and cancellation terms; the slight edge for Mochi is the sourcing transparency and continuity-plan disclosure.
Read the full Henry Meds review →
Top 3 compared
| Program | Score | Starts from | Lock-in | Time to Rx |
|---|---|---|---|---|
| Mochi Health | 7.6 | $178/mo | Month-to-month | 3 days |
| Henry Meds | 7.8 | $179/mo | Month-to-month | 2 days |
| Medvi | 7.4 | $179/mo | Month-to-month | 2 days |
Other strong picks
Frequently asked
Is compounded semaglutide still legal in 2026?
Yes, under specific 503A and 503B regulatory pathways with patient-specific prescriptions. The October 2024 FDA shortage resolution narrowed the legal basis for routine compounded semaglutide, but compounded prescribing continues for patients with documented clinical justification (cost, dosing flexibility, individual ingredient adjustments). The regulatory environment is fluid; expect further narrowing through 2026 to 2027.
Is compounded medication as effective as brand?
Active molecule (semaglutide or tirzepatide) is the same. Bioequivalence data on 503A-compounded GLP-1s is limited because 503A compounding doesn't require the same bioequivalence testing as generic FDA approval. Patient-reported outcomes are similar to brand in surveys, but the formal evidence base is thinner. The cost savings are real (often $200 to $1,000 monthly vs brand); the trade-off is the thinner evidence base and the regulatory exposure.
What happens if my pharmacy partner gets shut down mid-treatment?
This is the load-bearing risk question. Programs with a single pharmacy partner are most exposed. Programs with multiple partners or a public continuity plan can pivot. Mochi has historically communicated proactively during disruptions and offered to transfer prescriptions to alternative pharmacies. Cheaper programs sometimes leave patients in limbo. Read the program's published policy before signing up, or ask explicitly on intake.
Can I get tirzepatide compounded, or just semaglutide?
Both, from programs that still offer it. Tirzepatide compounded is the more legally fragile of the two due to Eli Lilly's coordinated litigation against compounded tirzepatide pharmacies through 2024 to 2025. Several large compounded tirzepatide operators have shut down or settled. Compounded semaglutide is more widely available but operates under the same narrowed FDA window post October 2024.
What's the cheapest brand-name alternative if compounded gets cut off?
NovoCare (Novo Nordisk's direct-to-consumer Wegovy pricing program) offers brand Wegovy at $199 to $499 monthly without insurance. LillyDirect offers brand Zepbound at $349 to $499 monthly through telehealth partners. These are the cash-pay floors on brand GLP-1; expect to pay 2x to 3x the compounded price for the regulatory clarity.
Should I stockpile if I'm worried about supply?
No. GLP-1 cold-chain storage is fragile (refrigerated 36 to 46 F for unopened pens, 30 days at room temperature for in-use pens). Stockpiling beyond 90 days creates expiration risk and storage problems. Better strategy: have a verified backup program ready (a second cash-pay compounded option or a verified brand path) so you can switch within 7 to 14 days if your primary supply is disrupted.
Is the price likely to go up?
Probably, slowly. Compounded GLP-1 prices have been roughly flat at $150 to $200 monthly through 2024 to 2026 as more 503A pharmacies entered the market. As enforcement narrows the operating pool, the surviving pharmacies have less competitive pressure, which historically pushes prices up. Expect the cheapest predictable cash-pay compounded floor to drift from $178 today toward $200 to $250 over 12 to 24 months.
Sources
- FDA: GLP-1 compounded drugs and safety concerns
- FDA: declaration that semaglutide shortage is resolved (October 2024)
- Eli Lilly press release on litigation against compounded tirzepatide
- USP 797 standards for sterile compounding (503A pharmacy quality)
Related
